Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 3
- Collinridge GL Peineau S Howland JG Wang YT Nat. Rev. Neurosci 2010 11 459 20559335
- 10.1016/0306-4522(95)00259-L · DOI · Paper page
- Machado-Vieira R Ibrahim L Henter ID Zarate CA Jr Pharmacol. Biochem. Behav 2012 100 678 21971560 PMC3253881 · DOI · Paper page
Cited by
Items 1,201–1,300 of 1,640
Erkizia-Santamaría, I., Fernández, L., Horrillo, I., Meana, J. J., & Ortega, J. E. (2026) · Neurobiology of Stress · doi:10.1016/j.ynstr.2026.100815 · Cited by 4
“These alterations closely parallel the structural abnormalities and deficits in neuroplasticity re-ported in the brains of patients with depression (Duman and Aghajanian, 2012; Page et al., 2024).”
Joy, J. (2015) · Journal of Health Education Research & Development · doi:10.4172/2380-5439.s1-001 · Cited by 1
Ketamine for Depression: A Mixed-Methods Study
Wolfson, P. E. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.75 · Cited by 3
Ketamine Treatment for Mood Disorders
Klise, A., Lerner, B. S., Ettensohn, M. F., & Levine, S. P. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180315-01 · Cited by 2
Neuroimaging Studies of Effects of Psychotherapy in Depression
Bauer, I. E., & Meyer, T. D. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.021 · Cited by 2
Changes in RNA expression levels during antidepressant treatment: a systematic review
Kim, H. K., Zai, G. C., Hennings, J. M., Müller, D. J., & Kloiber, S. M. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02394-0 · Cited by 2
“2015; Duman and Aghajanian 2012).”
Mood Disorders: Brain Imaging and Therapeutic Implications
(2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018 · Cited by 3
Алексеевич, Г. С., Levchuk, L. A., Simutkin, G. G., Ivanova, S. А., & Bokhan, N. A. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202312303182 · Cited by 4
Intranasal Delivery of Ketamine Induces Cortical Disinhibition
Qiao, X., Grieco, S. F., Yu, Z., Holmes, T. C., & Xu, X. (2023) · eNeuro · doi:10.1523/eneuro.0107-23.2023 · Cited by 3
“Despite these risks, ketamine has been called “ arguably the most important discovery in half a century ” by some within the fi eld of psychiatry (Duman and Aghajanian, 2012).”
BackgroundWang, H., Deng, S., & Bi, J. (2024) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2024.j007 · Cited by 2
Gärtner, M., Weigand, A., Meiering, M. S., Weigner, D., Carstens, L., Keicher, C., Hertrampf, R., Beckmann, C. F., Mennes, M., Wunder, A., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02977-x · Cited by 5
“This fi nding could give some insight into longer-lasting effects of ketamine, such as an increased metabolism in the respective brain region due to ketamine-induced synaptic plasticity [1, 55].”
Duan, X., Zhang, Y., Li, W., Su, N., & Sun, L. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.204 · Cited by 2
Li, L., Jiang, J., Zhong, S., Lin, J., Yao, Y., Kemp, G. J., Chen, Y., & Gong, Q. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae381 · Cited by 2
Lin, Z., Wang, Q., Li, X., Wang, C., Wang, R., Wang, C., Ding, H., Qian, L., Wan, X., Tian, X. Q., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1434659 · Cited by 2
“This may be due to depressive disorders leading to a reduction in neural synapses in brain structures such as the prefrontal cortex and hippocampus (48, 49), resulting in persistent cognitive impairments.”
BackgroundLow synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease
Jakobsson, P., Nilsson, J., Nygren, M., Zetterberg, H., Blennow, K., Constantinescu, R., Constantinescu, J., Brinkmalm, A., & Bäckström, D. C. (2025) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2025.123683 · Cited by 3
曹, 雄., & 高, 天. (2015) · Scientia Sinica Vitae · doi:10.1360/zc2016-46-2-212 · Cited by 2
Antidepressants: current mechanisms and new hopes
Greener, M. (2014) · Nurse Prescribing · doi:10.12968/npre.2014.12.1.38 · Cited by 2
Stewart, R. M., Wong, J. W. Y., Runions, K., Rao, P., Moore, J. K., Davies, S. R., von Ungern-Sternberg, B. S., Sommerfield, D. L., & Zepf, F. D. (2017) · Trials · doi:10.1186/s13063-017-2342-4 · Cited by 2
“These findings are significant because in the underlying neurobiology of depression, the NMDA receptor is thought to play a decisive role [8, 10, 11].”
BackgroundThe Impacts of Associative Memory Cells on Pathology
Wang, J. (2019) · Springer eBooks · doi:10.1007/978-981-13-9501-7_9 · Cited by 2
Electrophysiological Biomarkers for Mood Disorders
Ramakrishnan, N., Murphy, N., Selvaraj, S., & Cho, R. Y. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108623018.015 · Cited by 2
The Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
Involvement of a BH3-only apoptosis sensitizer gene Blm-s in hippocampus-mediated mood control
Huang, P., Yang, T., Yeh, C., Huang, S., Chang, H., Hung, Y.-F., Chu, W.-C., Cho, K., Lu, T., Kuo, P., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02184-6 · Cited by 4
“Our results thus support the synaptogenesis hypothesis of depression, which states that dysregulated synaptogenesis leads to abnormal electrophysiology of neurons and aberrant circuit activity that underlies depressive behavior [5].”
Result(2022) · Medical & Clinical Research · doi:10.33140/mcr.07.11.02 · Cited by 2
Neurobiology of Treatment in Pediatric Anxiety Disorders
Baumel, W. T., & Strawn, J. R. (2023) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2023.02.005 · Cited by 3
Thornton, O. R. (2023) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2023/v20i3399 · Cited by 3
“Increasingly, researchers have focused on the role of neuroplasticity and synaptic dysfunction in the development and maintenance of depression [12,13].”
BackgroundStructural Neuroimaging of Maltreatment and Inflammation in Depression
Redlich, R., Opel, N., Förster, K., Engelen, J., & Dannlowski, U. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811073-7.00016-7 · Cited by 2
Dynamic behavioral and molecular changes induced by chronic stress exposure in micePreprint
Prevot, T. D., Chatterjee, D., Knoch, J., Codeluppi-Arrowsmith, S. A., Misquitta, K. A., Fee, C., Newton, D. F., Oh, H., Sibille, E. L., & Banasr, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.07.443011 · Cited by 3
“4 consistently report synaptic loss [18-21], GABAergic dysfunction [22-26], and astroglial abnormalities 46 [27-31] in the PFC of brains from patients with MDD, or from animal models of chronic stress.”
BackgroundZhu, X., Zhang, F., You, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-790608/v1 · Cited by 2
Shen, S., Yu, R., Li, W., Liang, L., Han, Q.-Q., Huang, H., Li, B., Xu, S., Wu, G.-C., Zhang, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-829457/v1 · Cited by 2
Abdallah, C. G., & Krystal, J. H. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_7031-1 · Cited by 2
Short but Continuous Natural Pain for Depression Treatment and BeyondPreprint
Huang, M. (2018) · Preprints.org · doi:10.20944/preprints201805.0411.v1 · Cited by 1
Emotional Disorders in Development
Price, R. B., & Woody, M. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00024-4 · Cited by 4
Antidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association StudyPreprint
Davyson, E., Shen, X., Huider, F., Adams, M. J., Borges, K., McCartney, D. L., Barker, L., van Dongen, J., Boomsma, D. I., Weihs, A., et al. (2024) · medRxiv · doi:10.1101/2024.05.01.24306640 · Cited by 2
From psychache to neuroplasticity: A unified rescue-repair model of Ketamine’s anti-suicidal action
Domany, Y., & Solomon-Shashua, A. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106804 · Cited by 2
A nursing study on five-animal frolics in improving anxiety and depression of inpatients
Li, X., Wang, X., Fang, R. E. N., Jinyu, G. U. O., Zhang, S., & Tang, L. L. (2021) · Journal of Integrative Nursing · doi:10.4103/jin.jin_03_20 · Cited by 1
Lambe, E. K. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01502-5 · Cited by 1
Giannari, A. G., & Astolfi, A. (2023) · Neurocomputing · doi:10.1016/j.neucom.2023.127099 · Cited by 1
Chen, M.-H., Su, T., Lin, W.-C., Li, C., Wu, H.-J., Tsai, S., Bai, Y., Mao, W., & Tu, P. (2024) · Pharmacopsychiatry · doi:10.1055/a-2499-7207 · Cited by 4
“Inflam - mation leads to the production of quinolinic acid and kynurenic acid, which are an agonist and an antagonist, respectively, of the N-methyl-D-aspartate receptor [26, 27].”
Wirkmechanismen antidepressiver Pharmakotherapie: Gehirn und Psyche – Körper und Umwelt
Spangemacher, M., Reinwald, J., Adolphi, H., Kärtner, L., Mertens, L. J., Schmitz, C. N., & Gründer, G. (2025) · Der Nervenarzt · doi:10.1007/s00115-024-01786-3 · Cited by 1
“Auf zellulärer Ebene konnten Funkti-onsstörungen der Synapsen bei depres-siven Patient:innen und in Tiermodellen der Depression nachgewiesen werden [13, 25].”
Seo, M. K., Jeong, S., Cheon, W. S., Lee, D. Y., Lee, S., Lee, G.-H., Kang, D.-K., Seog, D., Kim, S.-H., Lee, J. G., et al. (2025) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.25.1269 · Cited by 2
“While the exact pathophysiology of depression remains unclear, increasing evidence points to impaired neuro-plasticity as a central factor [8-11].”
InfluentialSRT2104 enhances dendritic outgrowth and spine formation through Sirtuin 1-mediated mTORC1 signaling
Seo, M. K., Lee, J. G., Kim, J. H., Seog, D., Jeong, S., Kim, S. H., Lee, J. Y., & Park, S. W. (2025) · Scientific Reports · doi:10.1038/s41598-025-06203-6 · Cited by 2
MeCP2 regulates cell-type-specific functions of depressive-like symptoms in the nucleus accumbens
Bae, J., Kim, S. H., Jung, S. Y., Frankiv, N., Jin, H., Hwang, E. M., Kim, Y., Lee, S.-J., & Im, H. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01721-3 · Cited by 2
Black mulberry anthocyanins induce antidepressant-like effects via the BDNF/TrkB signaling pathway
Wang, X.-Y., Huang, J., Cheng, J., Huang, W., Xu, G., & Yi, L. (2025) · Food & Function · doi:10.1039/d5fo02698a · Cited by 6
Zhang, L., Xu, P., Yao, Z., Zhang, X., Wang, J., Hu, B., Feng, G., & Peng, H. (2025) · Neurocomputing · doi:10.1016/j.neucom.2025.131350 · Cited by 1
Zhao, X., Shah, P. T., Feng, L., Song, S., Feng, Y., Wu, C., Liu, R., Wang, Y., Zhang, S., & Wu, Z. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138366 · Cited by 1
Davarinejad, O., Komasi, S., Moradi, M., Nouraei, S., & Kazemisafa, F. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.09.030 · Cited by 2
Shi, C., Fan, D., Liu, K., Hu, X., Gao, Y., Liu, Q.-R., Wu, X., & Ji, M. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.09.078 · Cited by 1
Li, R., Yan, H., Chen, Y., Liu, Y., Tang, L., Yu, J., Liu, J., Wang, H., Wang, S., & Cheng, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02045 · Cited by 3
Hippocampal GPR17 down regulation ameliorates CMS-induced depression-like behaviors in mice
Xie, Z., Fan, B., Zhi, T., Wu, Y., Yang, Y., Wu, L., & Wu, X. G. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110757 · Cited by 1
Nadal‐Gratacós, N., Puigseslloses, P., Guzmán, L., Weiss, N., Pottie, E., Riera-Colomer, C., Lardeux, V., Thiriet, N., Wang, F.-H., Källsten, L., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03341-1 · Cited by 3
“This suggests a potential mechanistic link between 25C-NBF and structural plasticity, similar to other fast-acting antidepressants such as ketamine [82] and tryptamine-based psychedelics [14, 50, 83].”
Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Johnson, D. E., Meshkat, S., Kaczmarek, E. S., Rabin, J. S., Brudner, R. M., Chisamore, N., Doyle, Z., Bawks, J., Riva-Cambrin, J., Mansur, R. B., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111565 · Cited by 2
Advancing depression treatment: the role of sigma receptor ligands
Zhang, P., Ning, Z., Chen, H., Chen, J., Lu, Z., & Xu, F. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1691987 · Cited by 1
“Reduction of synapses in brain regions related to mood and cognition is linked to depression, and fast-acting antidepressants such as ketamine could promote synapse formation and repair stress-related synaptic damage (Duman and Aghajanian, 2012).”
Mitra, S., Kumar, A., Pandey, M., Gill, A., Sharma, M., Pundir, S., Jangir, M., & Chawla, G. (2025) · iScience · doi:10.1016/j.isci.2025.114296 · Cited by 7
“26,27 Given the limited efficacy and adverse side effects associated with existing pharmacological treatments, there has been growing interest in exploring natural plant-based alternatives with fewer side effects and multifactorial mechanisms of action.”
Gao, X., Lin, H., Wu, X., & Zhang, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-30168-1 · Cited by 1
Cao, P., Shen, S., Fang, Z., Tan, J., Wang, J., & Pan, N. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.12.003 · Cited by 1
“In the occurrence of depression, the same transporter and channel deficits impair neurotransmitter clearance and synaptic homeostasis, producing the synaptic dysfunction that underlies depressive symptomatology(Duman and Aghajanian, 2012).”
Lu, C., Gao, Z., Wei, Z., Zhu, Y., Shao, M., Jiang, Y., & Wu, L. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.121051 · Cited by 2
Yu, T., Cai, W., He, C., Xu, G., Song, G., Chen, K., & Liu, S. (2025) · Depression and Anxiety · doi:10.1155/da/7986150 · Cited by 4
“Additionally, both depression and the unique neuroplastic changes during adolescence, such as synaptic pruning [31], contribute to impaired information transmission and integration between brain regions.”
Yang, Y., Zhu, Y., Chen, B., Li, Y., Li, H., & Zhang, G. (2025) · Herkes için Spor ve Rekreasyon Dergisi · doi:10.56639/jsar.1720636 · Cited by 1
Qiu, H., Zhao, Y., Liu, C., Li, Y., Li, Y., & Zhu, H. (2026) · Brain-Apparatus Communication A Journal of Bacomics · doi:10.1080/27706710.2025.2610827 · Cited by 1
Xu, J.-Y., Li, C.-C., Zhang, H.-C., Guo, L.-J., Geng, M.-Y., He, X., Wang, L.-Y., Li, H., Wang, Y.-J., Xu, Q., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01708-2 · Cited by 1
Zhang, Y., Zhang, Q., Yang, Y., Cai, B., Ke, Z., Luo, J., Chen, H., & Ma, Y. (2026) · Brain stimulation · doi:10.1016/j.brs.2026.103033 · Cited by 1
Zhao, Y., Luo, Q., Ren, P., Zhang, R., Wen, Y., Lai, H., Fan, Y., Liu, X., Zhou, J., & Wu, X. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01535-w · Cited by 2
“Among these, alterations in synaptic number and functional level directly influence the development of depression [16], and long-term increases and decreases in synaptic strength are also intrinsically linked to depression in many ways [17].”
Nutraceuticals as adjuncts in managing neurodegenerative complications and their market
Datta, A., Sen, P., & Maiti, A. K. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100481 · Cited by 1
Chiang, P.-Y., Liao, C.-Y., Wu, C.-Y., Kao, W., Lin, Y.-T., Wei, P.-H., Tung, T.-H., & Huang, S.-Y. (2026) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2026.102747 · Cited by 3
Kang, J., Kong, N., Kim, S., & Lee, H. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07893-6 · Cited by 1
“These neurobiological processes are essential for maintaining neuronal function and have been previously implicated in the pathophysiology of depression [25, 26].”
Cheung, N. (2026) · Cureus · doi:10.7759/cureus.104031 · Cited by 1
“Rapid-acting antidepressants such as ketamine show that pushing synapses toward an AMPA-dominant state can release brain-derived neurotrophic factor (BDNF), activate mTOR, and trigger spine formation within hours, producing behavioral benefits that outpace traditional serotonergic agents [4].”
Pang, C., Sun, X., Zhao, J., Liang, X., Sun, L., Lin, Q., Sun, J., Lu, X., Dong, Q., Zhang, L., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2519586123 · Cited by 5
“Decreased expression of synaptic signaling proteins has also been reported in MDD patients (61).”
Ding, X., Wu, Y., Yang, J., Zhu, G., & Sun (2026) · Psychopathology · doi:10.1159/000551413 · Cited by 1
“At the structural and neurochemical levels, longitudinal studies have found that compared with healthy controls, patients with depression have progressive reduction in gray matter volume in the PFC and hippocampus [29].”
Classic psychedelics in obsessive–compulsive disorder: a circuit-based framework
Ali, S. S., Carhart-Harris, R. L., & Sieg, K. G. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00626-4 · Cited by 1
Yao, L., Yan, R., & Sun, C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1819436 · Cited by 5
“Furthermore, glucocorticoid resistance reduces the anti-inflammatory effects of glucocorticoids, which aggravates inflammation (Berkenbosch et al., 1987; Miller et al., 2002; Sapolsky et al., 1987; Besedovsky et al., 1986; Duman and Aghajanian, 2012).”
An, J., Li, X., Li, Z., Wang, J., & Pan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04417-y · Cited by 5
“…of biospecimens and imaging data across trials to enable pooled analyses; validation of candidate biomarkers (tryptophan metabolites, inflammatory markers, default mode network connectivity) in prospective studies; and pragmatic trials comparing biomarker-guided vs. unselected treatment [200, 201].”
Hu, M., Manglike, A. Y., Li, X., Wei, J., Lou, X., Liu, J., Tang, Z., He, W., Ji, G., Wang, W., et al. (2026) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2026.142150 · Cited by 1
Dias, L., Ferreira, S. G., Nabais, A. M., Silva, J., Cunha, R. A., & Agostinho, P. M. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70450 · Cited by 1
“…astrocytic A 2A R affects behavioral outputs such as memory performance (Matos et al. 2015; Orr et al. 2015) and modulates synaptic plasticity (Madeira, Lopes, et al. 2023; Dang et al. 2024), which alteration accompanies mood behavioral deficits in depressive conditions (Duman and Aghajanian 2012).”
Marsh, E. B., Lavretsky, H., Kasparian, N. A., Pike, N. A., Doyle, K. P., Aggarwal, N. T., Fullerton, H. J., Ivy, A. S., & Dlamini, N. (2026) · Stroke · doi:10.1161/str.0000000000000518 · Cited by 6
Feh, T. N., & Ninyin, C. (2026) · Greener Journal of Biomedical and Health Sciences · doi:10.15580/gjbhs.2026.1.041126053 · Cited by 1
“…the neurotransmitter as the main reason for mood disorders; however, more recent conceptualizations of mood disorders include more complex dysfunction in receptors, transporters, intracellular signaling cascades and the modulation of gene expression (Haroon et al., 2017; Duman & Aghajanian, 2012).”
Chen, C., Lin, L., Liu, Y., Wang, S., Wang, J., Zang, Y., Wang, J., Qin, W., & Zhang, B. Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03634-z · Cited by 2
“Synaptic expression levels are also associated with treatment response [43, 44].”
Tantipongpiradet, A., Davis, R., Altieri, E. A., O'Connor, K. E., & Murphy, K. J. (2026) · Neurobiology of Stress · doi:10.1016/j.ynstr.2026.100824 · Cited by 1
“…perturbations were most pronounced in excitatory glutamatergic neurons of the hippocampus, including CA1 and CA3 pyramidal neurons and dentate granule cells, cell types known to undergo dendritic atrophy and spine loss following chronic stress (Zaletel et al., 2017; Duman and Aghajanian, 2012).”
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1
Zhang, Z., & Zhou, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1831208 · Cited by 1
“Moreover, moderate-intensity exercise can mitigate depressive symptoms by enhancing neuroplasticity, similar to the mechanism of antidepressant medication (Duman and Aghajanian, 2012).”
Gasperoni, S., Ji, X., Sudre-Chinsky, C., Pajuelo, E. C., Zolfaghari, F. S., Boldemann, O., Hasan, M. M., Biagini, T., Umanski, D., Shemesh, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116825 · Cited by 1
Jiao, Y., Zhu, Z., Wang, R., He, B.-Y., Yao, H., Zhi-yong, Z., Shi, Y.-F., Wang, C., Cao, L., Liu, Y., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117749 · Cited by 1
The critical role of microglia in the stress response
Chen, K., Xuan, Z.-Y., Sun, B.-Y., Zhong, G.-N., Sun, X.-L., & Yan, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106894 · Cited by 1
Hünnemeyer, A., Ogama, Y., Crescenzo, F. D., Goeldner, R.-G., Harada, A., Katakabe, T., Scholz, A., Shatillo, Y., Süßmuth, S. D., & Keicher, C. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261481073 · Cited by 1
KETAMINE FOR DEPRESSION: AN OLD DRUG WITH A NEW INDICATION
Schepisi, C., Sabatini, D., & Nencini, P. (2014) · Cited by 1
Branch, P., Mathews, D. C., Richards, E. M., Niciu, M. J., Ionescu, D. F., Rasimas, J. J., & Zarate, C. A. (2013) · Cited by 1
Park, M. H., Choi, M., Kim, Y.-S., & Son, H. (2018) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2018.22.2.155 · Cited by 1
“Depression can be a devastating illness that results in personal disability and has been associated with altered brain structure and function [1].”
BackgroundEsketamine: the first glutamatergic drug for the management of treatment- resistant depression
Musazzi, L. (2020) · doi:10.36118/pharmadvances.03.2020.02 · Cited by 1
“pendent on restoring altered synaptic plasticity (3,10,12).”
BackgroundAMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants
Garro-Martínez, E., & Adell, A. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_6 · Cited by 1
Enzephalopathien bei psychiatrischen Erkrankungen
Reiff, J., & Braus, D. F. (2013) · Springer eBooks · doi:10.1007/978-3-642-36915-5_24 · Cited by 1
Internal and External Validity
Kazdin, A. E. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108993647.003 · Cited by 1
Günüç, S., & Koylu, E. O. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.02.013 · Cited by 2
Mo, J., Qinlong, X., Li, J., Zhaoxing, C., Ma, X., Qihua, Z., & He, G. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230418104418 · Cited by 2
Gupta, G. D., & Singh, D. (2023) · Current Gene Therapy · doi:10.2174/1566523223666230601145632 · Cited by 1
Sub-Anesthetic Dose of Ketamine Improves Cognitive Function and Motor Responses in Wistar Rats
Uahomo, P. O., Ibubeleye, V. T., Ezerioha, C. E., & Adheke, O. M. (2023) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2023/v19i4380 · Cited by 1
Алексеевич, Г. С., Levchuk, L. A., Simutkin, G. G., Ivanova, S. А., & Bokhan, N. A. (2023) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-023-01525-2 · Cited by 1
“Moreover, this disconnection is observed both between the hemispheres of the brain and within each hemisphere in different EEG frequency ranges, as has been con fi rmed in other studies [12, 14, 16].”
Regulation of Hippocampal GABAergic Transmission by Fluoxetine and Its Metabolite Norfluoxetine
Vázquez-Gómez, E., Hernández-Abrego, A., Mejía-Piedras, J., & García‐Colunga, J. (2024) · Receptors · doi:10.3390/receptors3010001 · Cited by 2
Raouf, P., Shalchyan, V., & Rostami, R. (2023) · National and International Iranian Conference on Biomedical Engineering (ICBME) · doi:10.1109/icbme61513.2023.10488623 · Cited by 1
“In more extreme instances, individuals may also face the risk of engaging in suicidal behavior [1].”
BackgroundJing, C., Zhong, X., Min, X., & Xu, H. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1388795 · Cited by 1
“Studies have shown that homeostatic control of synaptic connections plays a central role in the etiology and treatment of depression (Duman and Aghajanian, 2012).”
BackgroundZhang, C., Xu, C., Yan, H., Liang, J., Li, X., Tang, C., Yang, Y., Xie, G., & Guo, W. (2024) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2024.2412651 · Cited by 1
“Earlier research has proposed that disturbances in the homeostatic mechanisms regulating synaptic plasticity contribute to depression, resulting in the destabilisa-tion and loss of synaptic connections within the circuits responsible for mood and emotion (Duman and Aghajanian 2012).”
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.